Headache, often migrainous, is common in patients with antiphospholipid antibodies, whether or not they meet Sydney criteria for a definite diagnosis of Hughes syndrome. Migraine may be a harbinger of stroke in this patient population and even refractory migraine may be highly responsive to antithrombotic therapy in this clinical context.
Purpose
To summarize what is known to date about managing this important manifestation of the immune-mediated hypercoagulable Hughes syndrome.
Results
We provide a suggested management algorithm for refractory headache in this unique patient population.
Conclusion
Most neurologists don’t see or recognize many aPL-positive patients in their practice, so hematologists and rheumatologists who see these patients should recognize that refractory headache may be a manifestation of their immune-mediated hypercoagulable disorder and understand that the potential risks of not addressing this issue may be high.
SchofieldJRHughesHNBirleaM, et al.A trial of antithrombotic therapy in patients with refractory migraine and antiphospholipid antibodies: a retrospective study of 75 patients. Lupus2021; 30(4): 568–577.
2.
CuadradoMJKhamashtaMAHughesGRV. Migraine and stroke in young women. Q J Med2002; 93: 317–318.
3.
SilvestriniMCupiniLMMatteisM, et al.Migraine in patients with stroke and antiphospholipid antibodies. Headache1993; 33(8): 421–426.
4.
CerveraRBoffaMCKhamashtaMA, et al.The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus2009; 18(10): 889–893.
5.
CuadradoMJKhamashtaMAHughesGR. Sticky blood and headache. Lupus2001; 10(6): 392–393.
6.
NenciniPBaruffiMCAbbateR, et al. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke1992 Feb; 23(2): 189–193.
7.
HughesGRV. Heparin, antiphospholipid antibodies and the brain. Lupus2012; 21: 1039–1040.
8.
LeachIHLennoxGJaspanT, et al. Antiphospholipid antibody syndrome presenting with complex partial seizures and transient ischaemic attacks due to widespread small cerebral arterial thrombosis. Neuropathol Appl Neurobiol1989; 15: 579–584.
9.
ZiporenLPolak-CharconSKorczynDA, et al.Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin Dev Immunol2004; 11: 67–75.
10.
CavestroCMiccaGMolinariF, et al.Migraineurs show a high prevalence of antiphospholipid antibodies. J Thromb Haemost2011; 9: 1350–1354.
11.
TietjenGECollinsSA. Hypercoagulability and migraine. Headache2018; 58: 173–183.
12.
HughesGRV. Antiphospholipid syndrome, migraine and stroke. Lupus2010; 19: 555–556.
13.
SciasciaSSannaGKhamashtaMA, et al.The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum2015; 74: 2028–2033.
14.
SangleSD’CruzDPKhamashtaMA, et al.Antiphospholipid antibodies, systemic lupus erythematosus, and non-traumatic metatarsal fractures. Ann Rheum Dis2004; 63: 1241–1243.
15.
HughesGRCuadradoMJKhamashtaMA, et al.Headache and memory loss: rapid response to heparin inthe antiphospholipid syndrome. Lupus2001; 10(11): 778–778.
16.
AshersonRGiampauloDSinghS, et al. Dramatic response of severe headaches to anticoagulation in a patient with antiphospholipid syndrome. J Clin Rheumatol2007; 13(3): 173–174.
17.
KingEOdetteW. Complex migraine with subtherapeutic INR in antiphospholipid syndrome. Am J Med2012; 125(11): e9–e10.
18.
PignatelliPEttorreEMenichelliD, et al.Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management. Haematologica2020; 105(3): 562–572.
19.
SciasciaSAmigoMCRoccatelloD, et al.Diagnosing antiphospholipid syndrome: ‘extra-criteria’ manifestations and technical advances. Nat Review Rheumatol2017;13(9):548-560.
20.
Alijotas-ReigJEsteve-ValverdeEFerrer-OliverasR, et al.Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from the EUROAPS registry. Rheu2020; 59: 1306–1314.
21.
HughesGR. Hughes syndrome (the antiphospholipid syndrome): a disease of our time. Inflammopharmacology2011; 19(2): 69–73.
22.
SchofieldJRHassellKH. Dosing considerations in the use of the direct oral anticoagulants in the antiphospholipid syndrome. J Clin Pharm Ther2018; 43(1): 104–106.
23.
FrostCNepalSWangJ, et al.Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects. Br J Clin Pharmacol2013; 76(5): 776–786.
24.
Ruiz-IrastorzaGKhamashtaMAHuntBJ, et al.Bleeding and recurrent thrombosis in definite antiphospholipid syndrome. Arch Int Med2002; 162: 1164–1169.
25.
CerveraRSerranoRPons-EstelGJ, et al.Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheu Dis2015; 74(6): 1011–1018.
26.
DawwasGKLeonardCELewisJD, et al.Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data. Ann Int Med2022; 175(1): 20–28.
27.
GrangerCBAlexanderJHMcMurrayJJ, et al.Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med2011; 365: 981–992.
28.
DawwasGKDietrichECukerA, et al.Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation: a population-based cohort study. Ann Intern Med2021; 74(7): 910–919.
29.
ArachchillageDRMackieIJEfthymiouM, et al. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. J Throm Haemost2016; 14(11): 2177–2186.
